mikeb
Forum Replies Created
-
Posts
-
Thanks so Much Marion. That makes a lot of sense. Seems like a very promising drug if they can get the data together
THANKSThanks so much Marion.
I’ve been speaking with the clinical trial docs in Singapore, and they have been very helpful – but they cannot answer this question.
I do not have any contacts at ASLAN, so very interested if you can ask someone at ASLAN.
And yes – amazing speed these therapies are being developed. My hope/guess is that they are targeting markers, but learning along the way of potential non-targeted efficacy. The ASLAN one is very interesting in this regard since they had early breakthrough with CCA, but a lot of these markers are not prevalent in CCA I don’t believe.
Thanks so much
Mike B
Thanks to both of you
One clarification. The CCA-focused trial is phase 2 I believe: https://clinicaltrials.gov/ct2/show/NCT02609958?term=ASLAN001&rank=4 This is in Asia, and a mono study.
I still don’t understand the following – and not sure if relevant, or who could answer:
Although it’s a HER+ targeted therapy, they have opened some of the studies are open to non-HER (non-molecularly selected).
is this a normal step to open-up beyond target? Or would they only do this if they have some hope of non-target efficacy?
Thanks! Mike B
Hi Gavin (again)
I’ve been following ASLAN and spoken with one of the docs running the study in Singapore.
It’s an interesting drug since Asian development and most study – so you might not get many folks talking about it here since Asian (located) patients.
“87% Shrinkage” CCA PR Article: http://www.aslanpharma.com/download/Press%20Release%20-%20ASLAN%20ACT%20Genomics%20Collaboration.pdf
Although it’s a HER+ targeted therapy, they have opened some of the studies are open to non-HER (non-molecularly selected).
Is this normal procedure? Or do you think they have hypothesis that there is efficacy outside of Target?
https://clinicaltrials.gov/ct2/results?term=ASLAN001&Search=Search
Thanks so much Marion:
Another article out yesterday. Was Mayo the Phase I? Interesting that it was ‘non-clinical’…
http://tcbmag.com/News/Recent-News/2016/March/Mayo-Researchers-Make-Progress-In-Fight-Against-Ma
I understood that it was an inhibitor – but some hope in the this statement
“The Mayo researchers, along with Dr. Smith and others, concluded that Yeliva’s targeting of SK2 in the affected cells inhibited cancer proliferation and induced apoptosis – or self-destruction – in the cholangiocarcinoma cells.”
thx! Mike B
